389 related articles for article (PubMed ID: 17251307)
1. Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common.
Locuson CW; Hutzler JM; Tracy TS
Drug Metab Dispos; 2007 Apr; 35(4):614-22. PubMed ID: 17251307
[TBL] [Abstract][Full Text] [Related]
2. 1,2,3-Triazole-heme interactions in cytochrome P450: functionally competent triazole-water-heme complexes.
Conner KP; Vennam P; Woods CM; Krzyaniak MD; Bowman MK; Atkins WM
Biochemistry; 2012 Aug; 51(32):6441-57. PubMed ID: 22809252
[TBL] [Abstract][Full Text] [Related]
3. Theoretical study of the ligand-CYP2B4 complexes: effect of structure on binding free energies and heme spin state.
Harris DL; Park JY; Gruenke L; Waskell L
Proteins; 2004 Jun; 55(4):895-914. PubMed ID: 15146488
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions.
Hutzler JM; Melton RJ; Rumsey JM; Schnute ME; Locuson CW; Wienkers LC
Chem Res Toxicol; 2006 Dec; 19(12):1650-9. PubMed ID: 17173379
[TBL] [Abstract][Full Text] [Related]
5. Characterization of type II ligands in CYP2C9 and CYP3A4.
Ahlström MM; Zamora I
J Med Chem; 2008 Mar; 51(6):1755-63. PubMed ID: 18311908
[TBL] [Abstract][Full Text] [Related]
6. Engineering cytochrome c peroxidase into cytochrome P450: a proximal effect on heme-thiolate ligation.
Sigman JA; Pond AE; Dawson JH; Lu Y
Biochemistry; 1999 Aug; 38(34):11122-9. PubMed ID: 10460168
[TBL] [Abstract][Full Text] [Related]
7. Photochromic agents as tools for protein structure study: lapachenole is a photoaffinity ligand of cytochrome P450 3A4.
Gartner CA; Wen B; Wan J; Becker RS; Jones G; Gygi SP; Nelson SD
Biochemistry; 2005 Feb; 44(6):1846-55. PubMed ID: 15697210
[TBL] [Abstract][Full Text] [Related]
8. The binding of nitrogen-donor ligands to the ferric and ferrous forms of cytochrome P450 enzymes.
Mohamed H; Ghith A; Bell SG
J Inorg Biochem; 2023 May; 242():112168. PubMed ID: 36870164
[TBL] [Abstract][Full Text] [Related]
9. P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes.
Chiba M; Tang C; Neway WE; Williams TM; Desolms SJ; Dinsmore CJ; Wai JS; Lin JH
Biochem Pharmacol; 2001 Sep; 62(6):773-6. PubMed ID: 11551523
[TBL] [Abstract][Full Text] [Related]
10. Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.
Pearson JT; Hill JJ; Swank J; Isoherranen N; Kunze KL; Atkins WM
Biochemistry; 2006 May; 45(20):6341-53. PubMed ID: 16700545
[TBL] [Abstract][Full Text] [Related]
11. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
[TBL] [Abstract][Full Text] [Related]
12. Nitrogenous ligation at the sixth coordination position of the Thr-301 to Lys-mutated P450IIC2 heme iron.
Imai Y; Nakamura M
J Biochem; 1991 Dec; 110(6):884-8. PubMed ID: 1794978
[TBL] [Abstract][Full Text] [Related]
13. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
14. The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria.
Roberts AG; Campbell AP; Atkins WM
Biochemistry; 2005 Feb; 44(4):1353-66. PubMed ID: 15667229
[TBL] [Abstract][Full Text] [Related]
15. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
16. In vitro and pharmacophore insights into CYP3A enzymes.
Ekins S; Stresser DM; Williams JA
Trends Pharmacol Sci; 2003 Apr; 24(4):161-6. PubMed ID: 12707001
[TBL] [Abstract][Full Text] [Related]
17. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
Poli-Scaife S; Attias R; Dansette PM; Mansuy D
Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
[TBL] [Abstract][Full Text] [Related]
18. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
19. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding.
Scott EE; White MA; He YA; Johnson EF; Stout CD; Halpert JR
J Biol Chem; 2004 Jun; 279(26):27294-301. PubMed ID: 15100217
[TBL] [Abstract][Full Text] [Related]
20. Differential behavior of the sub-sites of cytochrome 450 active site in binding of substrates, and products (implications for coupling/uncoupling).
Narasimhulu S
Biochim Biophys Acta; 2007 Mar; 1770(3):360-75. PubMed ID: 17134838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
